from The American Heritage® Dictionary of the English Language, 4th Edition
- n. The formation or production of red blood cells.
from Wiktionary, Creative Commons Attribution/Share-Alike License
- n. The production of red blood cells in bone marrow.
from WordNet 3.0 Copyright 2006 by Princeton University. All rights reserved.
- n. the process of producing red blood cells by the stem cells in the bone marrow
The drug belongs to a class of drugs called erythropoiesis-stimulating agents, or ESAs, that have come under intense scrutiny from the FDA after being linked to higher risk of cardiovascular problems and death.
Anemia drugs, known as erythropoiesis-stimulating agents (ESAs), such as epoetin alfa (Epogen) and darbepoetin alfa (Aranesp), stimulate red blood cell production and are intended to reduce the number of blood transfusions required during chemotherapy.
Revenue from the Procrit anemia medicine fell 33% to $331 million in the U.S., on worries about the class of drugs to which it belongs, known as erythropoiesis-stimulating agents, or ESAs.
The products fall into a class of drugs known as erythropoiesis-stimulating agents, or ESAs.
Among the FDA's recent safety alerts about drugs already on the market, the agency warned consumers and doctors about increased cardiovascular risks and potential tumor growth in some patients with the class of anti-anemia drugs known as erythropoiesis-stimulating agents, including Amgen Inc. 's Epogen.
The FDA said the studies "provide further evidence of the risks of anemia drugs" known as erythropoiesis-stimulating agents, or ESAs.
The decisions by the FDA's advisers are a mixed result for the companies, which had proposed far more limited steps aimed at addressing growing evidence of potential risks for cancer patients taking the drugs, which are known as erythropoiesis-stimulating agents, or ESAs.
That's because the FDA instructs doctors to use the lowest dose necessary to prevent the need for a blood transfusion, which used to be the main treatment for anemia before the arrival of these drugs, known as erythropoiesis-stimulating agents.
Peginesatide belongs to a class of medicines known as erythropoiesis stimulating agents ESAs.
While the panel found data to show that the so-called erythropoiesis-stimulating agents or ESA could improve quality of life for patients and help keep them active, Reuters said most of the members on the advisory panel found enough evidence to conclude these drugs increase heart risks.
Wordnik is becoming a not-for-profit! Read our announcement here.